NIH PAR · NIAMS · UG3, UH3
PAR-25-141: NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
This NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) PAR, a re-issue of PAR-24-208, was re-issued as a result of the Simplifying Review of Research Project Grant Applications [link: https://grants.nih.gov/policy-and-compliance/policy-topics/peer-review/simplifying-review]. The Simplified Review changes in Section V. Application Review Information of the funding opportunity are the only changes that have been made. All other aspects of this funding opportunity remain the same.
- NOFO number
- PAR-25-141
- Type
- PAR
- Activity code
- UG3UH3
- Primary institute
- NIAMS · National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Clinical trials
- Required
- Posted
- Dec 9, 2024
- Opens
- Feb 4, 2025
- Expires
- Mar 5, 2027
PAR-25-141 due dates
2 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| March 04, 2025 | March 04, 2025 | Not Applicable | July 2025 | October 2025 | December 2025 |
| July 02, 2025 | July 02, 2025 | Not Applicable | November 2025 | January 2026 | April 2026 |
| November 04, 2025 | November 04, 2025 | Not Applicable | March 2026 | May 2026 | July 2026 |
| March 04, 2026 | March 04, 2026 | Not Applicable | July 2026 | October 2026 | December 2026 |
| July 02, 2026 | July 02, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| November 02, 2026 | November 02, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
| March 04, 2027 | March 04, 2027 | Not Applicable | July 2027 | October 2027 | December 2027 |
Projects funded under PAR-25-141
NIH RePORTER lists 5 projects funded under PAR-25-141 in FY2022–FY2026, with $1.9M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
5
Distinct projects, FY2022–FY2026
New awards
5
Type 1 (new project) award records
NIH funding
$1.9M
Award dollars under PAR-25-141, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 5 | 5 | $1.9M |
Institutions with the most funding
- Children's Hosp of Philadelphia$454K · 1 project
- Stanford University$446K · 1 project
- University of Connecticut Storrs$420K · 1 project
- Utah State Higher Education System--University of Utah$344K · 1 project
- Washington University$213K · 1 project
Funding institutes
- NIAMS$1.9M · 5
Activity codes funded
- UG35 records
Most recent new awards
- Dual Implant vs. Single Implant for Distal End of Femur (DISIDE) Trial (opens NIH RePORTER)
Utah State Higher Education System--University of Utah · 1UG3AR087112-01A1 · NIAMS · Notice Sep 17, 2026
$344KUG3
- Axial TReatment Agent Options; Responsiveness of Disease to Inhibition of Numerous Anti-Rheumatic pathways in Youth (AxTRAORDINARY) (opens NIH RePORTER)
Children's Hosp of Philadelphia · 1UG3AR087109-01A1 · NIAMS · Notice Sep 17, 2026
$454KUG3
- Noninvasive deep brain neuromodulation for refractory fibromyalgia (opens NIH RePORTER)
Washington University · 1UG3AR088418-01 · NIAMS · Notice Sep 17, 2026
$213KUG3
- GET SMART: A Sequential Multiple Assignment Randomized Trial of Graded Exposure Treatmentfor Youth with Chronic Musculoskeletal Pain (opens NIH RePORTER)
Stanford University · 1UG3AR086474-01A1 · NIAMS · Notice Sep 17, 2026
$446KUG3
- Remain in the Game: Dissemination of Primary Prevention to Keep Children Physically Active for Life (opens NIH RePORTER)
University of Connecticut Storrs · 1UG3AR087115-01 · NIAMS · Notice Aug 27, 2026
$420KUG3
What its predecessor PAR-24-208 funded
PAR-25-141 reissues PAR-24-208. Its funding history is the best guide to who wins under this program: 4 projects and $3.8M in FY2022–FY2026.
Projects funded
4
Distinct projects, FY2022–FY2026
New awards
2
Type 1 (new project) award records
NIH funding
$3.8M
Award dollars under PAR-24-208, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 2 | 2 | $601K |
| FY2026 | 2 | 0 | $3.2M |
Institutions with the most funding
- Henry Ford Health + Michigan State University Health Sciences$2.4M · 2 projects
- Johns Hopkins University$1.4M · 2 projects
Funding institutes
- NIAMS$3.8M · 4
Activity codes funded
- UG32 records
- UH32 records
Most recent new awards
- Accelerated Flap Coverage Versus Standard Timing in the Treatment of Severe Lower Extremity Musculoskeletal Injuries (opens NIH RePORTER)
Johns Hopkins University · 1UG3AR085896-01 · NIAMS · Notice Sep 8, 2025
$268KUG3
- Anti-CD38 isatuximab Immunotherapy in Hidradenitis Suppurativa: a randomized, double-blinded, placebo-controlled, seamless phase 2a/2b trial (opens NIH RePORTER)
Henry Ford Health + Michigan State University Health Sciences · 1UG3AR085895-01 · NIAMS · Notice Jul 30, 2025
$334KUG3
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-141. Contact the program officer at the institute that fits your research before applying.
- NIAMS · National Institute of Arthritis and Musculoskeletal and Skin Diseases
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Notices of Special Interest (NOSIs)
NIH has attached 2 NOSIs to PAR-25-141; none are active now. A NOSI flags a topic an institute wants to fund through this NOFO.
Award terms
- Application types allowed
- NewResubmissionRevision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Applications budgets are limited to 250,000 direct costs for the UG3 phase, but are not limited for the UH3 phase. However, budgets need to reflect the actual needs of the proposed project.
- Project period
- The scope of the proposed project should determine the project period. The project period is limited to six years: up to one year for the first phase UG3) and up to five years for the second phase UH3).   NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. 
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-24-208.
Other open NOFOs for UG3, UH3
- PAR-25-296Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)NCATS · next due Oct 19, 2026
- RFA-NS-27-007HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)NINDS · next due Oct 21, 2026
- PAR-27-015Community-Based Participatory Research to Advance Data and Practice Transformation (ADAPT) for Optimizing Oral Health for All (UG3/UH3 Clinical Trial Optional)NIDCR · next due Oct 16, 2026
- RFA-RM-27-012PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)RMOD · next due Oct 19, 2026
- RFA-RM-27-013Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)RMOD · next due Oct 19, 2026
- PAR-25-226Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)NIA · next due Oct 19, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.